Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Head & Neck 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Anemia 5Leukemia, Myelomonocytic, Chronic 4Anemia, Refractory, with Excess of Blasts 4Leukemia 3Thrombocytopenia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Paraproteinemias 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Myeloid, Acute 1GATA2 Deficiency 1Fever 1Fatigue 1Anemia, Refractory 1Agammaglobulinemia 1

Interventions

Epoetin Alfa 3Surveys and Questionnaires 2Darbepoetin alfa 2stinging nettle lectin 1peppermint oil 1ofatumumab 1epoetin beta 1Sodium Chloride 1Ritonavir 1Quality of Life 1Physical Therapy Modalities 1Metformin 1Lenalidomide 1Holistic Health 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fatigue × Lenalidomide × Classical hematology × Clear all
NCT01002755 2019-05-07

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

M.D. Anderson Cancer Center

Phase 2 Completed
36 enrolled 7 charts
Classical hematologyLymphoidOther hematologic neoplasm

Lymphadenopathy, Agammaglobulinemia, Fatigue, Fever, Lymphocytosis, Paraproteinemias, Thrombocytopenia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡